).
Contrasting viewpoints are common today between those leaning toward the right and to the left wing. In this issue of the Journal, Loupakis et al. (1) , have published a translational and clinico-pathologic report on the biological differences between metastatic colon cancers that arise from right-vs left-sided tumors. First, some caveats should be noted: 1) This study involves patients with metastatic disease. Whether the observed differences apply to primary resection of such tumors is unknown. 2) The publication represents a pooled analysis of one registry and two randomized trials involving chemotherapy with or without bevacizumab. As such, it could identify a predictive marker, but not prognostic outcomes, as there are no untreated control patients.
3) The analysis deals with a subset of "evaluable" patients in both the AVF2107 and NO16966 studies, though we do not know the criteria for this selection or whether some biases were introduced via this process. 4) As the investigators note, no statistical correction was made for multiple comparisons, and the results are, therefore, hypothesis generating.
Loupakis et al. performed a very thorough evaluation of gene expression for targets thought to be important in angiogenesis including ERCC-1, VEGF A, B, and C, and VEGF R-1 and R-2. The RNA expression by reverse-transcripterase polymerase chain reaction was associated with the outcomes for the use of bevacizumab in these trials and to right-vs left-sidedness. Only ERCC-1 expression (Supplementary Figure 1 , available online) showed statistically significant differences, with higher levels in the right colon tumors (median value 0.73 in the right side vs 0.65 for left-sided tumors compared with B-actin control, P = .042). Associations with prognostic or predictive value for bevacizumab are yet to be published.
The findings of this report are summarized in the Table 1 , showing the overall survival (OS) differences between the right and left-sided colon cancers. The PROVETTA registry (2) shows a very large difference (nearly double) in survival for left sideoriginating colon cancer compared with the right, but these survivals fall considerably outside the reported range for prospective trials, indicating some level of selection bias. In the pivotal AVF2107 trial (3), which led to the first approval of bevacizumab, the differences are nearly as pronounced and in fact are increased with bevacizumab to nearly the same hazard ratio (HR) as seen in PROVETTA (HR for right vs left side of 0.62 with bolus Irinotecan, 5FU and Leucovorin (IFL) and increasing to 0.49 with bevacizumab). The NO16966 (4) was a much larger trial (n = 1268) that used the Oxaliplatin, Leucovorin, and Bolus plus 46 hour infusional 5FU (FOLFOX) backbone and showed a small difference in progression-free survival (PFS) for the addition of bevacizumab but no difference in survival. We see improved survival for both right-and left-sided cancer with the FOLFOX regimen compared with IFL. We also find a greater bevacizumab effect on the right side vs the left side, and the right vs left hazard ratio is no longer statistically significant.
What conclusions can we draw from these data? Metastatic colon cancer originating from the right side of the colon and treated with chemotherapy appears to have shorter PFS and overall survival (OS) across the one registry (2) and the two large randomized trials (3,4) analyzed here. The differences are much more pronounced with irinotecan-based therapy (PROVETTA and AVF2107) than with oxaliplatin (NO16966). These studies therefore suggest a greater treatment effect and benefit on right side-originating colon cancer with the use of oxaliplatin-based chemotherapy, with differentially greater survival and PFS. This is particularly surprising given the fact that the gene expression of ERCC-1 is higher in the right colon (Supplementary Table 2 , available online), which would predict relative oxaliplatin resistance. Could this explain the relative lack of benefit of bevacizumab in the NO16966 study? It has been long debated why the AVF2107 trial (using IFL chemotherapy) was markedly positive for a survival effect of bevacizumab, with a statistically significant hazard ratio of 0.65, while the larger NO16966 study using FOLFOX failed to show a survival benefit for the addition of bevacizumab (OS HR = 0.89). The present report (1) provides an apparent explanation, as the data demonstrate a greater benefit of oxaliplatinbased chemotherapy overall and a disproportionate effect on the right-sided colon lesions, reducing the relative bevacizumab benefit. We see here, that oxaliplatin may be more effective than irinotecan for right-sided metastatic colon cancer and that bevacizumab further narrows the gap by differential treatment effect for lesions originating in the right side of the colon.
Where does this leave us? This interesting analysis gives rise to some important and testable biological hypotheses. The more conservative right may lean toward a platinum over a topo-1 inhibitor, and may benefit disproportionately from bevacizumab. This bears further investigation. However, at least when it comes to colon function, the right and left still work collaboratively, despite some innate differences! 
